Medulloblastoma Down under 2013: A report from the third annual meeting of the International Medulloblastoma Working Group

Acta Neuropathologica

Volumn 127, Issue 2, 2014, Pages 189-201

  Gottardo, Nicholas G ^a,b   Hansford, Jordan R ^a   McGlade, Jacqueline P ^b   Alvaro, Frank ^c   Ashley, David M ^d   Bailey, Simon ^f   Baker, David L ^e   Bourdeaut, Franck ^g   Cho, Yoon Jae ^h   Clay, Moira ^b   Clifford, Steven C ^f   Cohn, Richard J ⁱ   Cole, Catherine H ^a,j   Dallas, Peter B ^b   Downie, Peter ^k,n   Doz, François ^g,l   Ellison, David W ^ac   Endersby, Raelene ^b   Fisher, Paul G ^h   Hassall, Timothy ^m   Heath, John A ⁿ   Hii, Hilary L ^b   Jones, David T W ^o   Junckerstorff, Reimar ^a,p   Kellie, Stewart ^q   Kool, Marcel ^o   Kotecha, Rishi S ^a,b   Lichter, Peter ^o   Laughton, Stephen J ^r   Lee, Sharon ^a   McCowage, Geoff ^q   Northcott, Paul A ^o   Olson, James M ^s   Packer, Roger J ^t   Pfister, Stefan M ^o   Pietsch, Torsten ^u   Pizer, Barry ^v   Pomeroy, Scott L ^w   Remke, Marc ^z   Robinson, Giles W ^ac   Rutkowski, Stefan ^x   Schoep, Tobias ^b   Shelat, Anang A ^ac   Stewart, Clinton F ^ac   Sullivan, Michael ^y   Taylor, Michael D ^z   Wainwright, Brandon ^aa   Walwyn, Thomas ^a   Weiss, William A ^ab   Williamson, Dan ^f   Gajjar, Amar ^ac   more..

^a PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c JOHN HUNTER CHILDREN S HOSPITAL   (Australia)

^d BARWON HEALTH   (Australia)

^e PATHWEST LABORATORY MEDICINE   (Australia)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g INSTITUT CURIE   (France)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ SYDNEY CHILDREN'S HOSPITAL   (Australia)

^j UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^k MONASH CHILDREN S HOSPITAL   (Australia)

^l UNIVERSITÉ PARIS DESCARTES   (France)

^m ROYAL CHILDREN'S HOSPITAL   (Australia)

ⁿ ROYAL CHILDREN'S HOSPITAL   (Australia)

^o GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^p ROYAL PERTH HOSPITAL   (Australia)

^q CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^r STARSHIP CHILDREN S HOSPITAL   (New Zealand)

^s UNIVERSITY OF WASHINGTON   (United States)

^t CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^u UNIVERSITY OF BONN   (Germany)

^v ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^w BOSTON CHILDREN S HOSPITAL   (United States)

^x UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^y CHRISTCHURCH HOSPITAL   (New Zealand)

^z HOSPITAL FOR SICK CHILDREN   (Canada)

^aa UNIVERSITY OF QUEENSLAND   (Australia)

^ab UNIVERSITY OF CALIFORNIA   (United States)

^ac ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; DEAD BOX PROTEIN;

BLOOD BRAIN BARRIER; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CONFERENCE PAPER; ENZYME CONFORMATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENOME ANALYSIS; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; ISOCHROMOSOME; ISOCHROMOSOME 17Q; LONG TERM SURVIVAL; MEDULLOBLASTOMA; METHYLATION; MOLECULAR PATHOLOGY; NERVE FIBER GROWTH; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WHOLE GENOME BISULFITE SEQUENCING;

ADOLESCENT; ANIMALS; ANTINEOPLASTIC AGENTS; AUSTRALIA; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; GENOMICS; HUMANS; INTERNATIONAL AGENCIES; MEDULLOBLASTOMA; MICE;

EID: 84896692613     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-013-1213-7     Document Type: Conference Paper

References (52)

1. Cho YJ, Tsherniak A, Tamayo P et al (2011) Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29(11):1424-1430
2. Eberhart CG, Kepner JL, Goldthwaite PT et al (2002) Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 94(2):552-560
3. Ellison DW (2010) Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathol 120(3):305-316
4. Ellison DW, Dalton J, Kocak M et al (2011) Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121(3):381-396
5. Ellison DW, Kocak M, Dalton J et al (2011) Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29(11):1400-1407
6. Ellison DW, Onilude OE, Lindsey JC et al (2005) Beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23(31):7951-7957
7. Fattet S, Haberler C, Legoix P et al (2009) Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 218(1):86-94
8. Gajjar A, Chintagumpala M, Ashley D et al (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7(10):813-820
9. Gajjar A, Pizer B (2010) Role of high-dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors. Pediatr Blood Cancer 54(4):649-651
10. Hovestadt V, Remke M, Kool M et al (2013) Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol 125(6):913-916
11. Jakacki RI, Burger PC, Zhou T et al (2012) Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study. J Clin Oncol 30(21):2648-2653
12. Jones DT, Jager N, Kool M et al (2012) Dissecting the genomic complexity underlying medulloblastoma. Nature 488(7409):100-105
13. Kool M, Koster J, Bunt J et al (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 3(8):e3088
14. Kortmann RD, Kuhl J, Timmermann B et al (2000) Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46(2):269-279
15. Lannering B, Rutkowski S, Doz F et al (2012) Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 30(26):3187-3193
16. Laughton SJ, Merchant TE, Sklar CA et al (2008) Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J Clin Oncol 26(7):1112-1118
17. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97-109
18. Mabbott DJ, Penkman L, Witol A, Strother D, Bouffet E (2008) Core neurocognitive functions in children treated for posterior fossa tumors. Neuropsychology 22(2):159-168
19. Mabbott DJ, Spiegler BJ, Greenberg ML et al (2005) Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood. J Clin Oncol 23(10):2256-2263
20. Massimino M, Antonelli M, Gandola L et al (2013) Histological variants of medulloblastoma are the most powerful clinical prognostic indicators. Pediatr Blood Cancer 60(2):210-216
21. McManamy CS, Lamont JM, Taylor RE et al (2003) Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol 62(6):627-632
22. Milla LA, Arros A, Espinoza N et al (2014) Neogenin1 is a sonic hedgehog target in medulloblastoma and is necessary for cell cycle progression. Int J Cancer 134(1):21-31
23. Milligan PA, Brown MJ, Marchant B et al (2013) Model-based drug development: a rational approach to efficiently accelerate drug development. Clin Pharmacol Ther 93(6):502-514
24. Mulhern RK, Kepner JL, Thomas PR et al (1998) Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. J Clin Oncol 16(5):1723-1728
25. Mulhern RK, Palmer SL, Merchant TE et al (2005) Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 23(24):5511-5519
26. Northcott PA, Jones DT, Kool M et al (2012) Medulloblastomics: the end of the beginning. Nat Rev Cancer 12(12):818-834
27. Northcott PA, Korshunov A, Pfister SM, Taylor MD (2012) The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 8(6):340-351
28. Northcott PA, Korshunov A, Witt H et al (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29(11):1408-1414
29. Northcott PA, Shih DJ, Peacock J et al (2012) Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488(7409):49-56
30. Northcott PA, Shih DJ, Remke M et al (2012) Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol 123(4):615-626
31. Oyharcabal-Bourden V, Kalifa C, Gentet JC et al (2005) Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. J Clin Oncol 23(21):4726-4734
32. Packer RJ, Gajjar A, Vezina G et al (2006) Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24(25):4202-4208
33. Packer RJ, Goldwein J, Nicholson HS et al (1999) Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group Study. J Clin Oncol 17(7):2127-2136
34. Packer RJ, Hoffman EP (2012) Neuro-oncology: understanding the molecular complexity of medulloblastoma. Nat Rev Neurol 8(10):539-540
35. Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A (2013) Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. Neuro Oncol 15(1):97-103
36. Palmer SL, Armstrong C, Onar-Thomas A et al (2013) Processing speed, attention, and working memory after treatment for medulloblastoma: an international, prospective, and longitudinal study. J Clin Oncol 31(28):3494-3500
37. Parsons DW, Li M, Zhang X et al (2011) The genetic landscape of the childhood cancer medulloblastoma. Science 331(6016):435-439
38. Pfister S, Remke M, Benner A et al (2009) Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27(10):1627-1636
39. Pugh TJ, Weeraratne SD, Archer TC et al (2012) Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488(7409):106-110
40. Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM (2001) Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol 19(15):3470-3476
41. Robinson G, Parker M, Kranenburg TA et al (2012) Novel mutations target distinct subgroups of medulloblastoma. Nature 488(7409):43-48
42. Rutkowski S, Bode U, Deinlein F et al (2005) Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352(10):978-986
43. Rutkowski S, von Hoff K, Emser A et al (2010) Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol 28(33):4961-4968
44. Ryan SL, Schwalbe EC, Cole M et al (2012) MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol 123(4):501-513
45. Schwalbe EC, Williamson D, Lindsey JC et al (2013) DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol 125(3):359-371
46. Smoll NR, Drummond KJ (2012) The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci 19(11):1541-1544
47. Spiegler BJ, Bouffet E, Greenberg ML, Rutka JT, Mabbott DJ (2004) Change in neurocognitive functioning after treatment with cranial radiation in childhood. J Clin Oncol 22(4):706-713
48. Tabori U, Sung L, Hukin J et al (2005) Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian Pediatric Brain Tumor Consortium Study. Cancer 103(9):1874-1880
49. Taylor MD, Northcott PA, Korshunov A et al (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123(4):465-472
50. Taylor RE, Bailey CC, Robinson K et al (2003) Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 21(8):1581-1591
51. Thomas PR, Deutsch M, Kepner JL et al (2000) Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 18(16):3004-3011
52. Thompson MC, Fuller C, Hogg TL et al (2006) Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24(12):1924-1931